Eisai Expands in Israeli Market With Approval of Halaven

Description

Eisai Expands in Israeli Market With Approval of Halaven PR Newswire HATFIELD, England, July 10, 2012 HATFIELD, England, July 10, 2012 /PRNewswire/ -- Metastatic breast cancer treatment Halaven® (eribulin) provides a statistically significant overall survival benefit for women with the disease ®Halaven (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received registration approval from the Israeli health authorities. Prior therapy should have included two common types of chemotherapy, an anthracycline and a taxane, unless patients were not suitable for these treatments. Eribulin has been proven to significantly extend overall survival in patients with [1]metastatic breast cancer, compared to other single agent chemotherapies. Following marketing authorisation, Eisai and Neopharm group, its partner in Israel, plan to launch the product by the end of Eisai's financial year 2012 (31 March 2013). Commenting on the launch of eribulin in Israel, Nick Butland, Regional Director MPBU, Eisai Europe Limited said, "The launch of eribulin in Israel will boost Eisai's geographical and patient reach in this region. Eisai's entry into this market is aligned with the company's wider strategy of increasing access to our medicines based on affordability, availability and adoption by making products available in new markets.

Informations

• Publié par: eisai-europe-limited
• Nombre de lectures: 22
• Langue: English

Extrait

Eisai Expands in Israeli Market With Approval

of Halaven

PR Newswire

HATFIELD, England, July 10, 2012

HATFIELD,

England

,

July 10, 2012

/PRNewswire/ --

Metastatic breast cancer treatment Halaven® (eribulin) provides a

statistically significant overall survival benefit for women with the

disease

Halaven

®

(eribulin), a novel treatment for patients with locally advanced or

metastatic breast cancer who have progressed after at least two

chemotherapeutic regimens for advanced disease, has recently received

registration approval from the Israeli health authorities. Prior therapy should

have included two common types of chemotherapy, an anthracycline and a

taxane, unless patients were not suitable for these treatments.

Eribulin has been proven to significantly extend overall survival in patients with

metastatic breast cancer, compared to other single agent chemotherapies.

[1]

Following marketing authorisation, Eisai and Neopharm group, its partner in

Israel

, plan to launch the product by the end of Eisai's financial year 2012 (

31

March 2013

).

Commenting on the launch of eribulin in

Israel

, Nick Butland, Regional Director

MPBU, Eisai Europe Limited said, "The launch of eribulin in

Israel

will boost

Eisai's geographical and patient reach in this region. Eisai's entry into this

market is aligned with the company's wider strategy of increasing access to our

medicines based on affordability, availability and adoption by making products

available in new markets."

"We are excited about the opportunity to work with Eisai to introduce Halaven

into this region", stated Mr. David Fuhrer, Chairman of the Neopharm Group.

"Working in partnership means that together we can actively introduce

innovative licensed products to meet the needs of the region and improve the

health and quality of life of patients."

The Israeli launch of eribulin will allow access for women to a treatment not

previously available to them and further supports Eisai's

human health care

(hhc

) mission to satisfy unmet medical needs and contribute to the health and

well being of people worldwide. Eisai is dedicated to discovering, developing

and producing innovative oncology therapies that can help make a difference

and impact the lives of patients and their families.

Notes to Editors

Halaven

®

(eribulin)

Eribulin is a non-taxane, microtubule dynamics inhibitor indicated for the

treatment of patients with breast cancer who have previously received at least

two chemotherapeutic regimens for metastatic disease and whose prior

therapy should have included an anthracycline and a taxane.

[1]

Eribulin belongs

to a class of antineoplastic agents, the halichondrins, which are natural

products, isolated from the marine sponge Halichondria okadai. It is believed to

work by inhibiting the growth phase of microtubule dynamics without affecting

the shortening phase and sequesters tubulin into non-productive aggregates.

Eribulin is approved in the European Union,

USA

,

Switzerland

,

Japan

, and

Singapore

. In

Europe

, eribulin is currently commercially available in

Austria

,

Denmark

,

Estonia

,

France

,

Finland

,

Germany

,

Iceland

,

Ireland

,

Italy

,

Japan

,

Luxembourg

,

Netherlands

,

Norway

,

Poland

,

Sweden

,

Switzerland

, and the

United Kingdom

.

About Eisai

Eisai is one of the world's leading R&D-based pharmaceutical companies and

has defined its corporate mission as "giving first thought to patients and their

families and to increasing the benefits health care provides," which we call

human health care (hhc). Eisai recently expanded their UK Hatfield facility

which now supports the company's growing European, Middle Eastern, African

and Russian (EMEA) business.

Eisai concentrates its R&D activities in three key areas:

Neuroscience, including: Alzheimer's disease, multiple sclerosis, neuropathic pain,

epilepsy, depression

Oncology including: anticancer therapies; tumour regression, tumour suppression,

antibodies, etc and supportive cancer therapies; pain relief, nausea

Vascular/Immunological reaction including: acute coronary syndrome, atherothrombotic

disease, rheumatoid arthritis, psoriasis, Crohn's disease

With operations in the U.S.,

Asia

,

Europe

and its domestic home market of

Japan

, Eisai employs more than 11,000 people worldwide. In

Europe

, Eisai

undertakes sales and marketing operations in over 20 markets, including the

United Kingdom

,

France

,

Germany

,

Italy

,

Spain

,

Switzerland

,

Sweden

,

Ireland

,

Austria

,

Denmark

,

Finland

,

Norway

,

Portugal

,

Iceland

,

Czech Republic

,

Slovakia

,

the Netherlands

,

Belgium

,

Luxembourg

,

Middle East

and

Russia

.

For further information please visit our web site http://www.eisai.com

About Neopharm Group

Neopharm Group, established in 1941, is one of

Israel's

leading providers of

innovative integrated solutions across the spectrums of healthcare and life

science.

Throughout the years, the group has evolved into a diversified health care

company. At Neopharm Group, we specialize in building leadership and

combining strengths in the areas of pharmaceuticals, biologic drugs, orphan

drugs, vaccines, hospital products, medical devices, medical and scientific

equipment, diagnostics, OTC, nutritionals, consumer healthcare products and

home therapy.

Neopharm is the exclusive representative and partner of leading multinational

bio-pharma and consumer healthcare brands including: Abbott, Actelion,

Alexion, Celgene, Gilead, Johnson & Johnson, Novartis Vaccines, Pfizer, Pfizer

Consumer Health among others.

Neopharm Group currently employs over 500 talented staff within 5 companies.

Neopharm holds the prestigious rank of

Israel's

second-largest marketing group

in the Israeli healthcare and life science market. Our revenues exceed

$300

million

, making us the 58th largest Israeli company as per D&B's Largest Israeli

Enterprises 2011.

For further information please visit our web site:

http://www.neopharmgroup.com

1. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin

monotherapy versus treatment of physician's choice in

patients with metastatic breast cancer (EMBRACE): a

phase 3 open-label randomised study. The Lancet.

2011; 377: 914 -923

July 2012

/ Eribulin-UK2174